Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.

Mörén, Lina; Perryman, Richard; Crook, Tim; Langer, Julia K; Oneill, Kevin; Syed, Nelofer; Antti, Henrik

Mörén, Lina; Perryman, Richard; Crook, Tim; Langer, Julia K; Oneill, Kevin; Syed, Nelofer; Antti, Henrik.

Afiliação

Mörén L; Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden.
Perryman R; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
Crook T; St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.
Langer JK; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
Oneill K; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
Syed N; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK. n.syed@imperial.ac.uk.
Antti H; Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden. henrik.antti@umu.se.

BMC Cancer ; 18(1): 268, 2018 03 08.

Article em En | MEDLINE | ID: mdl-29519248

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google